[Heteroimmune hemolytic anemia associated with antilymphocyte globulin treatment in a patient with aplastic anemia].

This research article discusses the case study of a 24-year-old male who underwent treatment for severe aplastic anemia (SAA) using equine-antilymphocyte globulin. However, he developed severe heteroimmune hemolytic anemia as a complication linked to this treatment procedure.

Introduction and Case Description

• The study reviews the case of a 24-year-old male patient suffering from severe aplastic anemia, a condition where the body fails to produce enough new blood cells.
• The patient was treated using equine-antilymphocyte globulin (ALG), a common therapy for SAA. However, he developed a severe case of heteroimmune hemolytic anemia as a side effect.
• Heteroimmune hemolytic anemia is a condition where the immune system starts attacking and destroying the red blood cells, leading to anemia.

The Role of Antilymphocyte Globulin (ALG) and Complications

• The research explains that this adverse reaction was likely due to anti-species pan-agglutinin antibodies present in the ALG.
• Despite efforts taken to eliminate contaminating anti-erythrocyte and anti-platelet antibodies from ALG, only partial absorption is achieved, and the patient can acquire the remaining antibodies.
• Typical complications from this treatment include neutropenia and thrombocytopenia. However, anti-erythrocyte antibodies can also be detected in patients and contribute to hemolytic anemia.

Understanding the Severity and Potential Undetected Cases

• The severity of hemolysis in this patient, with significantly decreased hemoglobin levels, was unusual, and seems to be connected with administering the ALG when the patient’s hematocrit was close to normal following earlier anabolic treatment.
• The study suggests that similar episodes of hemolysis might go unnoticed in severely anemic patients with high transfusion demands.

Implications for Testing and Transfusions

• The acquired reactivity to the direct antiglobulin test and the positive results for unexpected antibodies can be attributed to the presence of antibodies reacting with a globulin component shared by human and horse sera in the commercially available antihuman globulin serum (AGS).
• Neutralizing the AGS with the patient-administered ALG removed these cross-reacting antibodies, allowing for reliable transfusion compatibility testing and confirmation of the absence of hidden alloantibodies or warm autoantibodies.